This study is being carried out to determine the effect of dapagliflozin on cardiovacular outcomes when added to current background therapy in patients with type 2 diabetes with either established cardiovacular disease or cardiovascular risk factors.
Oral dose (od)
Oral dose (od)
Buenos Aires, Argentina
Buenos Aires, Argentina
CABA, Argentina
Ciudad Autonoma Buenos Aires, Argentina
Ciudad Autonoma de Buenos Aire, Argentina
Córdoba, Argentina
Córdoba, Argentina
Córdoba, Argentina
La Plata, Argentina
La Plata, Argentina
Lanús, Argentina
Mar del Plata, Argentina
Mar del Plata, Argentina
Ramos Mejía, Argentina
Rosario, Argentina
Rosario, Argentina
San Nicolás, Argentina
Santa Fe, Argentina